Stratasys (NSDQ:SSYS) and Origin announced that they signed an agreement to produce more than 1 million nasopharyngeal COVID-19 testing swabs per week.
Under the agreement, Stratasys is slated to market and promote Origin’s 3D-printed swabs to healthcare providers and other U.S. testing centers. Each Origin One 3D printer can produce batches of 1,500 Origin NP O1 swabs at a time and multiple times daily. Origin intends to introduce a streamlined process to produce approximately 190,000 swabs per day, totaling 1.3 million per week.
Get the full story at our sister site, Medical Design & Outsourcing.